Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Product Performance of a New Silicone Hydrogel Contact Lens

NCT04901897 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this study is to evaluate the product performance of kalifilcon A, compared to the Johnson \& Johnson Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens and Alcon DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses when worn by current soft contact lens wearers on a daily disposable wear basis.

Conditions Studied

Interventions

  • DEVICE senofilcon A
  • DEVICE delefilcon A
  • DEVICE kalifilcon A

Study Locations (20)

California

  • Bausch Site 406 — Azusa
  • Bausch Site 430 — Los Angeles
  • Bausch Site 419 — San Diego
  • Bausch Site 435 — San Francisco
  • Bausch Site 432 — Sunnyvale
  • Bausch Site 409 — Torrance

Florida

  • Bausch Site 415 — Jacksonville
  • Bausch Site 434 — Jacksonville
  • Bausch Site 405 — Sarasota

Hawaii

  • Bausch Site 437 — Honolulu
  • Bausch Site 401 — ‘Aiea

Alabama

  • Bausch Site 433 — Birmingham

Arizona

  • Bausch Site 431 — Scottsdale

Colorado

  • Bausch Site 416 — Denver

Georgia

  • Bausch Site 412 — Decatur

Kansas

  • Bausch Site 414 — Leavenworth

Trial Details

FieldValue
Enrollment Target 805 participants
Start Date 2019-07-31
Est. Completion 2019-10-09
Phase NA

Sponsor

Bausch & Lomb Incorporated

78 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04901897

The ClinicalTrials.gov registry entry for NCT04901897 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 805 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 78 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 3 interventions — of which senofilcon A is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04901897 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Hawaii. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04901897 about?

NCT04901897 is a clinical study titled "Product Performance of a New Silicone Hydrogel Contact Lens". The objective of this study is to evaluate the product performance of kalifilcon A, compared to the Johnson \& Johnson Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens and Alcon DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses when worn by current soft c...

What is the current status of trial NCT04901897?

This trial is currently completed. It is a NA study. The enrollment target is 805 participants. The study started on 2019-07-31. Estimated completion is 2019-10-09.

What conditions does trial NCT04901897 study?

This clinical trial studies the following conditions: Myopia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04901897?

The interventions under investigation include: senofilcon A (DEVICE), delefilcon A (DEVICE), kalifilcon A (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04901897?

This trial is sponsored by Bausch & Lomb Incorporated, which has 78 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04901897 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial